Microfluidic Biochip Flow-Trap Array for Digital Biomarker Counting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current biomarker detection methods, such as digital ELISA and lateral flow immunoassays, face limitations in sensitivity, specificity, and reproducibility due to optical interference, bead aggregation, environmental variability, and subjective colorimetric interpretations, particularly in low-concentration samples.
Innovation Solution
A microfluidic chip with a dual-layer structure incorporating hydrophobic and hydrophilic interfaces and a flow-trap junction (FTJ) array for controlled bead capture and array formation, utilizing digital immunochromatography to enhance sensitivity and reproducibility, and an adaptive algorithm for signal differentiation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If magnetic beads are used for capture, then single-molecule counting sensitivity is achieved, but optical interference attenuates fluorescence intensity and reduces signal-to-noise ratio
Solution Approach 1:
The patent extracts the magnetic property from the bead core by using silica beads instead of magnetic beads, removing the source of optical interference while maintaining the capture function through alternative means (e.g., surface coating with capture antibodies). This separates the capture function from the optical interference, allowing fluorescence detection to proceed with high signal intensity.
Solution Approach 2:
The patent changes the material parameter of the bead core from magnetic material (Fe3O4) to silica material (SiO2), which has different optical properties. This parameter change eliminates the refractive index mismatch and magnetic interference that attenuated fluorescence signals, while the capture function is maintained through surface functionalization.
2Measurement precision
If magnetic beads are used for capture, then biomarker detection is enabled, but bead aggregation reduces assay specificity and precision
Solution Approach 1:
The patent removes the magnetic property that causes aggregation by substituting magnetic beads with silica beads. Without magnetic fields, beads no longer aggregate, maintaining individual bead identity and preventing nonspecific interactions, thereby improving assay specificity while preserving detection capability.
Solution Approach 2:
The patent applies capture antibodies specifically on the bead surface rather than relying on magnetic properties for capture. This localized functionalization ensures specific biomarker binding at the bead surface without causing aggregation, as the capture mechanism is chemical rather than magnetic.
3Adaptability or versatility
If conventional ELISA is used, then widespread applicability is maintained, but sensitivity limits prevent detection of scarce biomarkers in minute samples
Solution Approach 1:
The patent segments the sample into individual beads, each capable of capturing and concentrating target molecules. This segmentation allows detection of scarce biomarkers by distributing them across many individual capture events, transforming the continuous analog signal into discrete digital events that can be counted with high precision.
Solution Approach 2:
The patent uses numerous identical silica beads as copies of the capture element, each capable of binding the target biomarker. This multiplication of capture units increases the overall detection sensitivity while maintaining the simplicity and versatility of the ELISA format.
4Measurement precision
If digital ELISA with magnetic beads is used, then attomolar sensitivity is achieved, but imaging throughput is restricted and bead array density is limited
Solution Approach 1:
The patent changes the bead material from magnetic to silica, which improves optical properties and enables higher bead array densities. The enhanced optical clarity allows better imaging at higher densities, increasing throughput while maintaining attomolar sensitivity through the digital counting approach.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system achieves high-sensitivity, automated biomarker detection with reduced sample volume requirements, improved capture efficiency, and robustness against environmental variations, enabling simultaneous detection of multiple biomarkers with enhanced throughput and scalability.
Implementation Method 1
The microfluidic chip comprises a dual-layer structure with hydrophobic and hydrophilic interfaces
Implementation Method 2
The microfluidic chip comprises a dual-layer structure with hydrophobic and hydrophilic interfaces
Implementation Method 3
The flow-trap junction (FTJ) array creates controlled flow resistance to capture microbeads
Implementation Method 4
utilizing digital immunochromatography to enhance sensitivity and reproducibility
Data Source
AI summary
Compositions and methods for quantitating target molecules from samples using digital chromatography implemented on microfluidic biochips are described. A microfluidic device including two symmetric microfluidic channels, each incorporating hydrophobic filter structures and high-density hydrophilic flow-trap junction arrays (FT-JA) is provided. Centrally positioned turbine valves increase the resistance in the flow channel directing the fluid laterally through the trap channel. The microfluidic device, e.g., a chip, is configured to facilitate the simultaneous, parallel capture of control and test samples including a target molecule, e.g., a biomarker, immobilized on microscale particles, e.g., microbeads, by capturing the beads in the FT-JA. In some forms, a microfluidic chip quantifies biomarkers within a biological sample with 90% efficiency for imaging within a compact area, e.g., 30 mm2, in a low time frame, e.g., 80 seconds. Exemplary biomarkers that can be quantified according to the described methods include tumor antigens and biomarkers derived from pathogens. Exemplary samples include tears, plasma and blood.